BACKGROUND: The Thoratec left ventricular assist device (LVAD; Thoratec Laboratories Corporation, USA) was used as a bridge to transplantation at the Montreal Heart Institute. LVAD patients were activated on the waiting list as soon as they were in suitable clinical status. OBJECTIVE: To analyze the effect of introducing the Thoratec LVAD in the heart transplantation program at the Montreal Heart Institute. METHODS: The results of 16 LVAD patients and 20 patients who underwent heart transplantation without LVAD support between January 2000 and February 2002 were reviewed. RESULTS: Sixteen patients in cardiogenic shock underwent emergency implantation of a Thoratec LVAD following acute myocardial infarction (five patients), acute viral cardiomyopathy (five patients), idiopathic cardiomyopathy (three patients), postpartum cardiomyopathy (two patients) and failure to wean from cardiopulmonary bypass (one patient). Thirteen of 16 (81%) LVAD patients underwent heart transplantation, and three LVAD patients were not listed and died from multiorgan failure. The wait for transplantation averaged 17+/-19 days in LVAD patients compared with 87+/-66 days for the 20 patients undergoing transplantation without LVAD support (P=0.01). Survival 12 months following transplantation averaged 84+/-10% in LVAD supported patients and 90+/-7% in those without LVAD support (P=0.6). CONCLUSION: The use of Thoratec LVAD as a bridge to transplantation did not prolong the wait for a donor of patients without LVAD support (United Network Organ Sharing status II). Moreover, listing patients as soon as they appear suitable for transplantation resulted in a short period of LVAD support and a good rate of survival one year after transplantation.
BACKGROUND: The Thoratec left ventricular assist device (LVAD; Thoratec Laboratories Corporation, USA) was used as a bridge to transplantation at the Montreal Heart Institute. LVADpatients were activated on the waiting list as soon as they were in suitable clinical status. OBJECTIVE: To analyze the effect of introducing the Thoratec LVAD in the heart transplantation program at the Montreal Heart Institute. METHODS: The results of 16 LVADpatients and 20 patients who underwent heart transplantation without LVAD support between January 2000 and February 2002 were reviewed. RESULTS: Sixteen patients in cardiogenic shock underwent emergency implantation of a Thoratec LVAD following acute myocardial infarction (five patients), acute viral cardiomyopathy (five patients), idiopathic cardiomyopathy (three patients), postpartum cardiomyopathy (two patients) and failure to wean from cardiopulmonary bypass (one patient). Thirteen of 16 (81%) LVADpatients underwent heart transplantation, and three LVADpatients were not listed and died from multiorgan failure. The wait for transplantation averaged 17+/-19 days in LVADpatients compared with 87+/-66 days for the 20 patients undergoing transplantation without LVAD support (P=0.01). Survival 12 months following transplantation averaged 84+/-10% in LVAD supported patients and 90+/-7% in those without LVAD support (P=0.6). CONCLUSION: The use of Thoratec LVAD as a bridge to transplantation did not prolong the wait for a donor of patients without LVAD support (United Network Organ Sharing status II). Moreover, listing patients as soon as they appear suitable for transplantation resulted in a short period of LVAD support and a good rate of survival one year after transplantation.
Authors: Ismaïl El-Hamamsy; Frédéric Jacques; Louis P Perrault; Denis Bouchard; Pphilippe Demers; Michel White; Guy B Pelletier; Normand Racine; Michel Pellerin; Michel Carrier Journal: Can J Cardiol Date: 2009-02 Impact factor: 5.223